+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Characterization of a prolactin-daunomycin ligand as a probe for drug targeting

Characterization of a prolactin-daunomycin ligand as a probe for drug targeting

Molecular and Cellular Endocrinology 46(3): 245-252

Conjugates of ovine prolactin and daunomycin were prepared for use as affinity-labelled drug carriers in cancer cells carrying the prolactin receptor. The binding affinity of the conjugates to prolactin receptors in rat liver membrane preparations and in viable granulosa cells derived from estradiol- and pregnant mare serum gonadotropin (PMSG)-treated immature female rats was less than an order of magnitude lower than prolactin. The toxicity of the conjugate in cultured granulosa cells was dependent upon the concentration of the daunomycin present in the culture. The cytotoxic effect of the ligand was abolished by the addition of free prolactin or NH4Cl to the granulosa cell cultures. These conjugates may be useful probes in drug targeting against hormone-sensitive cancer.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 039520147

Download citation: RISBibTeXText

PMID: 3017783

DOI: 10.1016/0303-7207(86)90006-7

Related references

In vitro toxicity of an ovine prolactin daunomycin ligand is mediated by the prolactin receptor. Acta Endocrinologica Suppl. 108(267): 127-128, 1985

Daunomycin targeting to human colon carcinoma cells using drug anti carcino embryonic antigen conjugates. Proceedings of the American Association for Cancer Research & American Society of Clinical Oncology 22: 211, 1981

Thermodynamic characterization of daunomycin-DNA interactions: microcalorimetric measurements of daunomycin-DNA binding enthalpies. Biochemistry 30(40): 9799-9809, 1991

A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. Plos one 8(8): E72938, 2013

A simple assay for determining the drug effect of daunomycin in cancer cells Direct correlation of NPM-translocation with apoptosis induced by daunomycin. Proceedings of the American Association for Cancer Research Annual Meeting 39: 429, 1998

Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. Critical Reviews in Therapeutic Drug Carrier Systems 18(1): 1-76, 2001

Improved targeting of ligand-modified adenovirus as a new near infrared fluorescence tumor imaging probe. Bioconjugate Chemistry 22(4): 567-581, 2011

A multivalent ligand for the mannose-6-phosphate receptor for endolysosomal targeting of an activity-based probe. Angewandte Chemie 53(41): 10975-8, 2014

A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate. Journal of Medicinal Chemistry 27(12): 1602-1607, 1984

Daunomycin and daunomycinol plasma levels measured by high performance liquid chromatography after perfusions of daunomycin and daunomycin dna complex in rabbits a preliminary report. Archives Internationales de Pharmacodynamie et de Therapie 226(2): 344-345, 1977

A new probe for targeting drug delivery system. Medical Hypotheses 72(1): 43-44, 2009

Drug pharmacophores covalently linked to the red cell surface are active without prior release. Drug targeting of renin with a synthetic ligand conjugated to red blood cells. Journal of Drug Targeting 7(2): 113-130, 1999

Characterization of a biotin-conjugated ovine prolactin ligand. Molecular and Cellular Endocrinology 56(1-2): 71-79, 1988

Design, Synthesis, and Evaluation of a Diazirine Photoaffinity Probe for Ligand-Based Receptor Capture Targeting G Protein-Coupled Receptors. Molecular Pharmacology 95(2): 196-209, 2019

Characterization of a novel human prolactin receptor isoform with altered ligand binding. Molecular Biology of the Cell 10(Suppl. ): 184a, 1999